Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12270861 | 0.91 | TSHR (0.41) | TSHRMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12158330 | 0.88 | TSHR (0.49) | TSHRMAPK1ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL12158343 | 0.88 | TSHR (0.42) | TSHRMAPK1ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL27051341 | 0.85 | TSHR (0.48) | TSHRMAPK1ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL13384368 | 0.84 | ALDH1A1 (0.43) | TSHRMAPK1ALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL14156747 | 0.84 | TSHR (0.72) | TSHRMAPK1ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL216984 | 0.82 | TSHR (0.50) | TSHRMAPK1ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL36499 | 0.82 | TSHR (0.67) | TSHRMAPK1ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL12158328 | 0.82 | TSHR (0.46) | TSHRMAPK1ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL16314638 | 0.82 | TSHR (0.46) | TSHRMAPK1ALDH1A1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585387-B1 | PEHAM dendrimers for use in agriculture | STARPHARMA PTY LTD (AU) | 2017-03-07 | — | — | US | disclosed |
| US-9585387-B1 | PEHAM dendrimers for use in agriculture | STARPHARMA PTY LTD (AU) | 2017-03-07 | — | — | US | disclosed |
| US-7985424-B2 | Dendritic polymers with enhanced amplification and interior functionality | DENDRITIC NANOTECHNOLOGIES INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985424-B2 | Dendritic polymers with enhanced amplification and interior functionality | DENDRITIC NANOTECHNOLOGIES INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-7981444-B2 | Dendritic polymers with enhanced amplification and interior functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981444-B2 | Dendritic polymers with enhanced amplification and interior functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| WO-2009110971-A2 | PROCESS FOR CONVERTING MULTIFUNCTIONAL ALIPHATIC ALCOHOLS | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070244296-A1 | Dendritic Polymers with Enhanced Amplification and Interior Functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244296-A1 | Dendritic Polymers with Enhanced Amplification and Interior Functionality | DENDRITIC NANOTECHNOLOGIES, INC. (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298006-A1 | Dendritic Polymers With Enhanced Amplification and Interior Functionality | MYD88, TLR3, TMEM97 | TSHR 3651/4885MAPK1 4174/4885ALDH1A1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.